ADAM17 and ovarian carcinoma: Indeed we and others demonstrated that cisplatin treatment leads to upregulation of ADAM17 and increased release of growth factors that mediate cisplatin resistance in ovarian cancer and hepatocellular carcinoma, respectively26,44.